• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Moderna, Inc. - Common Stock (NQ:MRNA)

    49.81 +6.81 (+15.84%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Moderna, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Why Moderna Stock Surged Today ↗
    The vaccine maker is expanding beyond its COVID-focused offerings. 
    Via The Motley Fool
    These S&P500 stocks are moving in today's after hours session ↗
    Via Chartmill
    Discover which S&P500 stocks are making waves on Wednesday. ↗
    Via Chartmill
    News headline image
    Moderna Stock Skyrockets To 52-Week High: What&#39;s Behind The Surge? ↗
    Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study. 
    Via Benzinga
    What's going on in today's session: S&P500 movers ↗
    Via Chartmill
    ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
    Via Stocktwits
    Topics Intellectual Property
    Gapping S&P500 stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Moderna (MRNA) Shares Skyrocket, What You Need To Know
    Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year follow-up study of... 
    Via StockStory
    Topics Artificial Intelligence Government
    News headline image
    Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
    BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges. 
    Via Stocktwits
    News headline image
    Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? ↗
    Via MarketBeat
    News headline image
    Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
    Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
    Via Stocktwits
    News headline image
    3 Healthcare Stocks Walking a Fine Line
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
    Via StockStory
    Topics Stocks
    Exploring the top movers within the S&P500 index during today's session. ↗
    Via Chartmill
    These S&P500 stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
    As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property Lawsuit
    Top S&P500 movers in Friday's pre-market session ↗
    Via Chartmill
    Chips and Checks: AI and Banks Lead Wall Street's Charge ↗
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
    As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
    Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
    Via Chartmill
    Topics Government
    These S&P500 stocks are moving in today's session ↗
    Via Chartmill
    Stay informed with the top movers within the S&P500 index on Tuesday. ↗
    Via Chartmill
    News headline image
    The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
    As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
    Via MarketMinute
    Topics Economy Intellectual Property World Trade
    Top S&P500 movers in Monday's session ↗
    Via Chartmill
    What's going on in today's session: S&P500 movers ↗
    Via Chartmill
    These S&P500 stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
    In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
    Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
    Via PredictStreet
    Topics Initial Public Offering Intellectual Property
    News headline image
    3 Unprofitable Stocks We Keep Off Our Radar
    Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
    Via StockStory
    News headline image
    Dow Jones Erases Record Highs in 200-Point Reversal as Economic Data Shifts
    The Dow Jones Industrial Average (DJIA) experienced a jarring reversal on Wednesday, January 7, 2026, tumbling more than 200 points after hitting a fresh all-time high earlier in the session. The... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.